AtaiBeckley Inc. is positioned favorably due to promising clinical data from its BPL-003 program, demonstrating improved MADRS scores and an increased remission rate after multiple doses, which indicates a robust potential for enhanced efficacy in treating treatment-resistant depression. The company estimates that BPL-003 could capture approximately 20% market share by 2035 based on its unique clinical profile and rapid time to market. The company's shares continue to trade on Nasdaq under the symbol 'ATAI.' It also reported that its common stock was added to the Nasdaq Biotechnology Index in December 2025.
Cyborg Score Rationale
According to 6 analysts, ATAI has a Strong Buy consensus rating as of Mar 3, 2026, with 83% of analysts recommending a Strong Buy, 17% recommending Buy. The company has significant clinical momentum with lead asset BPL-003 showing robust efficacy data, though it remains pre-commercial with ongoing cash burn and clinical-stage risks.
Top Insights
AtaiBeckley NV has outlined its outlook for 2026, highlighting anticipated clinical milestones and recent corporate developments ahead of its participation in the JP Morgan 44th Annual Healthcare Conference.
The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder.
AtaiBeckley Inc announced the appointment of Michael Faerm as chief financial officer, effective March 9, 2026.
AtaiBeckley Inc. exhibits a concerning trend in the efficacy of its lead product BPL-003, as highlighted by a noticeable decline in efficacy from Week 4 to Week 6 in Phase 2 clinical trials, raising questions about the sustainability of its treatment effects.
Named Competitors
MNMD — Psychedelic-derived therapeutic development for mental health
CMPS — Psilocybin-based COMP360 therapy platform for treatment-resistant depression
CYBN — Psychedelic-based drug development and mental health innovations
Recent Developments
(March 2026) Michael Faerm appointed Chief Financial Officer effective March 9, 2026
(December 2025) AtaiBeckley added to Nasdaq Biotechnology Index
(December 2025) Company completed redomiciliation to the United States
(November 2025) Positive Phase 2b Open-Label Extension data for BPL-003 supporting safety and efficacy of second dose in TRD patients
Open the full interactive AtaiBeckley Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.